Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Vidaza FDA Approved for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

June 2022 Vol 8 No 3

In May 2022, the FDA approved Vidaza (azacitidine for injection; from Celgene) for the treatment of young patients with newly diagnosed juvenile myelomonocytic leukemia, a condition that can develop into myelodysplastic syndromes. Vidaza was previously approved for the treatment of patients with myelodysplastic syndromes.

This approval was based on results of a clinical trial that evaluated Vidaza in 18 pediatric patients with juvenile myelomonocytic leukemia. All the patients received Vidaza on days 1 to 7 of a 28-day cycle, for a minimum of 3 cycles and a maximum of 6 cycles. Patients were included in the study if they did not have disease progression or were not ready for a transplant between cycles 4 and 6.

Of the 18 patients in the study, half (9) of the patients had clinical responses to treatment with Vidaza. Of these 9 patients, 3 patients had a complete response (no sign of cancer) to therapy and 6 patients had a partial response. The average time to response was 1.2 months.

The majority (94%) of the patients received a transplant after treatment with Vidaza, and the average time to the transplant was 4.6 months.

The most common side effects reported with Vidaza in pediatric patients with juvenile myelomonocytic leukemia were fever, rash, upper respiratory tract infection, and anemia.

Recommended For You